πŸ‡ΊπŸ‡Έ FDA
Patent

US 9034881

Treatment for vitiligo

granted A61KA61K31/145A61K31/505

Quick answer

US patent 9034881 (Treatment for vitiligo) held by Rigel Pharmaceuticals, Inc. expires Mon May 14 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue May 19 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 14 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/145, A61K31/505, A61K31/506, A61K45/06